ID   MT-2
AC   CVCL_2631
SY   MT2; MT-2J; MT-2Org
DR   BTO; BTO_0005492
DR   CLO; CLO_0007888
DR   EFO; EFO_0022393
DR   CLDB; cl3596
DR   CLDB; cl3597
DR   BEI_Resources; ARP-237
DR   BioSample; SAMN03472437
DR   ChEMBL-Cells; CHEMBL3307558
DR   ChEMBL-Targets; CHEMBL614184
DR   Cosmic; 919158
DR   ECACC; 08081401
DR   ECACC; 93121518
DR   IARC_TP53; 27003
DR   JCRB; JCRB1210
DR   JCRB; NIHS0527
DR   PubChem_Cell_line; CVCL_2631
DR   Wikidata; Q54906935
RX   CelloPub=CLPUB00542;
RX   PubMed=1765142;
RX   PubMed=2985879;
RX   PubMed=3001699;
RX   PubMed=3003193;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=6198871;
RX   PubMed=6275274;
RX   PubMed=6281119;
RX   PubMed=7662981;
RX   PubMed=7832798;
RX   PubMed=8957066;
RX   PubMed=9510473;
RX   PubMed=12920029;
RX   PubMed=15638862;
RX   PubMed=16850164;
RX   PubMed=19220422;
RX   PubMed=22608188;
RX   PubMed=25544500;
RX   PubMed=26940204;
RX   PubMed=28357668;
RX   PubMed=29892436;
RX   PubMed=32187573;
WW   Info; Thermo Fisher; -; https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-576.html
CC   Population: Japanese.
CC   Characteristics: Was established by co-cultivation of cells from a 45 year old female T-cell leukemia patient with cord leukocytes from a male infant (CelloPub=CLPUB00542).
CC   Virology: HTLV-1 producing cell line. Contains 11 integrated HTLV-1 proviruses: one complete proviral genome, six copies of a provirus with an internal deletion of 5.3 kb, one copy of a provirus with an internal deletion of 3.9 kb, one copy of a provirus with a 6.2 kB deletion from 5'LTR to position 6257 and two copies of a provirus composed of LTR only.
CC   Virology: Susceptible to infection by hepatitis C virus (HCV) (PubMed=7832798).
CC   Transformant: NCBI_TaxID; 11908; Human T-lymphotropic virus 1 (HTLV-1).
CC   Discontinued: ECACC; 93121518; probable.
CC   Discontinued: JCRB; NIHS0527; true.
CC   Derived from site: In situ; Umbilical cord blood; UBERON=UBERON_0012168.
CC   Cell type: Regulatory T-cell; CL=CL_0000815.
ST   Source(s): JCRB=JCRB1210; PubMed=28357668
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,13
ST   D16S539: 9,11
ST   D18S51: 12,14
ST   D21S11: 29,30
ST   D3S1358: 16,17
ST   D5S818: 13
ST   D7S820: 8,13
ST   D8S1179: 11,14
ST   FGA: 23,24
ST   Penta D: 10,11
ST   Penta E: 15,16
ST   TH01: 6,10
ST   TPOX: 10,11
ST   vWA: 16
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   <1D
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 34
//
RX   CelloPub=CLPUB00542;
RA   Miyoshi I., Taguchi H., Kubonishi I., Yoshimoto S., Ohtsuki Y.,
RA   Shiraishi Y., Akagi T.;
RT   "Type C virus-producing cell lines derived from adult T cell leukemia.";
RL   Gann Monogr. Cancer Res. 28:219-228(1982).
//
RX   PubMed=1765142; DOI=10.1016/0014-5793(91)81402-t;
RA   Orita S., Saiga A., Takagi S., Tanaka T., Okumura K., Aono Y.,
RA   Hinuma Y., Igarashi H.;
RT   "A novel alternatively spliced viral mRNA transcribed in cells
RT   infected with human T cell leukemia virus type 1 is mainly responsible
RT   for expressing p21X protein.";
RL   FEBS Lett. 295:127-134(1991).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   Carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3001699; DOI=10.1073/pnas.82.24.8359; PMCID=PMC390915;
RA   Kiyokawa T., Seiki M., Iwashita S., Imagawa K., Shimizu F.,
RA   Yoshida M.;
RT   "p27x-III and p21x-III, proteins encoded by the pX sequence of human
RT   T-cell leukemia virus type I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:8359-8363(1985).
//
RX   PubMed=3003193; DOI=10.4049/jimmunol.136.4.1322;
RA   Lee J.C., Rebar L., Young P., Ruscetti F.W., Hanna N., Poste G.;
RT   "Identification and characterization of a human T cell line-derived
RT   lymphokine with MAF-like activity distinct from interferon-gamma.";
RL   J. Immunol. 136:1322-1328(1986).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6198871; DOI=10.18926/AMO/32400;
RA   Oda T., Watanabe S., Nakamura T.;
RT   "Type C virus particles produced in human T-cell lines derived from
RT   acute lymphoblastic leukemia and a leukemic T-lymphoid malignancy.";
RL   Acta Med. Okayama 37:529-533(1983).
//
RX   PubMed=6275274; DOI=10.1038/294770a0;
RA   Miyoshi I., Kubonishi I., Yoshimoto S., Akagi T., Ohtsuki Y.,
RA   Shiraishi Y., Nagata K., Hinuma Y.;
RT   "Type C virus particles in a cord T-cell line derived by co-cultivating
RT   normal human cord leukocytes and human leukaemic T cells.";
RL   Nature 294:770-771(1981).
//
RX   PubMed=6281119;
RA   Miyoshi I., Kubonishi I., Yoshimoto S., Shiraishi Y.;
RT   "A T-cell line derived from normal human cord leukocytes by
RT   co-culturing with human leukemic T-cells.";
RL   Gann 72:978-981(1981).
//
RX   PubMed=7662981; DOI=10.1182/blood.V86.6.2350.bloodjournal8662350;
RA   Imada K., Takaori-Kondo A., Akagi T., Shimotohno K., Sugamura K.,
RA   Hattori T., Yamabe H., Okuma M., Uchiyama T.;
RT   "Tumorigenicity of human T-cell leukemia virus type I-infected cell
RT   lines in severe combined immunodeficient mice and characterization of
RT   the cells proliferating in vivo.";
RL   Blood 86:2350-2357(1995).
//
RX   PubMed=7832798; DOI=10.1006/bbrc.1995.1123;
RA   Kato N., Nakazawa T., Mizutani T., Shimotohno K.;
RT   "Susceptibility of human T-lymphotropic virus type I infected cell
RT   line MT-2 to hepatitis C virus infection.";
RL   Biochem. Biophys. Res. Commun. 206:863-869(1995).
//
RX   PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x; PMCID=PMC5920998;
RA   Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N.,
RA   Liu C., Kondo E., Minowada J., Akagi T.;
RT   "Metastatic potential of lymphoma/leukemia cell lines in SCID mice is
RT   closely related to expression of CD44.";
RL   Jpn. J. Cancer Res. 87:1070-1077(1996).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=12920029; DOI=10.1182/blood-2003-04-1043;
RA   Chung H.-K., Young H.A., Goon P.K.C., Heidecker G., Princler G.L.,
RA   Shimozato O., Taylor G.P., Bangham C.R.M., Derse D.D.;
RT   "Activation of interleukin-13 expression in T cells from
RT   HTLV-1-infected individuals and in chronically infected cell lines.";
RL   Blood 102:4130-4136(2003).
//
RX   PubMed=15638862; DOI=10.1111/j.1365-2141.2004.05289.x;
RA   Hasegawa H., Yamada Y., Harasawa H., Tsuji T., Murata K., Sugahara K.,
RA   Tsuruda K., Ikeda S., Imaizumi Y., Tomonaga M., Masuda M., Takasu N.,
RA   Kamihira S.;
RT   "Sensitivity of adult T-cell leukaemia lymphoma cells to tumour
RT   necrosis factor-related apoptosis-inducing ligand.";
RL   Br. J. Haematol. 128:253-265(2005).
//
RX   PubMed=16850164; DOI=10.1007/s10495-006-9235-4;
RA   Miura Y., Nishimura Y., Katsuyama H., Maeda M., Hayashi H., Dong M.-L.,
RA   Hyodoh F., Tomita M., Matsuo Y., Uesaka A., Kuribayashi K., Nakano T.,
RA   Kishimoto T., Otsuki T.;
RT   "Involvement of IL-10 and Bcl-2 in resistance against an
RT   asbestos-induced apoptosis of T cells.";
RL   Apoptosis 11:1825-1835(2006).
//
RX   PubMed=19220422; DOI=10.1111/j.1600-0609.2009.01211.x;
RA   Kamihira S., Terada C., Sasaki D., Yanagihara K., Tsukasaki K.,
RA   Hasegawa H., Yamada Y.;
RT   "Aberrant p53 protein expression and function in a panel of
RT   hematopoietic cell lines with different p53 mutations.";
RL   Eur. J. Haematol. 82:301-307(2009).
//
RX   PubMed=22608188; DOI=10.1016/j.scitotenv.2012.04.043;
RA   Maeda M., Yamamoto S., Chen Y., Kumagai-Takei N., Hayashi H.,
RA   Matsuzaki H., Lee S., Hatayama T., Miyahara N., Katoh M.,
RA   Hiratsuka J.-i., Nishimura Y., Otsuki T.;
RT   "Resistance to asbestos-induced apoptosis with continuous exposure to
RT   crocidolite on a human T cell.";
RL   Sci. Total Environ. 429:174-182(2012).
//
RX   PubMed=25544500; DOI=10.1038/cmi.2014.123; PMCID=PMC4711675;
RA   Hamano R., Wu X.-Q., Wang Y.-T., Oppenheim J.J., Chen X.;
RT   "Characterization of MT-2 cells as a human regulatory T cell-like cell
RT   line.";
RL   Cell. Mol. Immunol. 12:780-782(2015).
//
RX   PubMed=26940204; DOI=10.1007/s13577-016-0136-8;
RA   Hashikura Y., Umeki K., Umekita K., Nomura H., Yamamoto I.,
RA   Hasegawa H., Yanagihara K., Okayama A.;
RT   "The diversity of the structure and genomic integration sites of
RT   HTLV-1 provirus in MT-2 cell lines.";
RL   Hum. Cell 29:122-129(2016).
//
RX   PubMed=28357668; DOI=10.1007/978-1-4939-6872-5_11;
RA   Raimondi V., Minuzzo S.A., Ciminale V., D'Agostino D.M.;
RT   "STR profiling of HTLV-1-infected cell lines.";
RL   Methods Mol. Biol. 1582:143-154(2017).
//
RX   PubMed=29892436; DOI=10.1098/rsos.172472; PMCID=PMC5990783;
RA   Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M.,
RA   Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S.,
RA   Satoh M., Shimizu N., Kohara A.;
RT   "Screening for 15 pathogenic viruses in human cell lines registered at
RT   the JCRB Cell Bank: characterization of in vitro human cells by viral
RT   infection.";
RL   R. Soc. Open Sci. 5:172472-172472(2018).
//
RX   PubMed=32187573; DOI=10.1016/j.envint.2020.105654;
RA   Yamamoto S., Lee S., Matsuzaki H., Kumagai-Takei N., Yoshitome K.,
RA   Sada N., Shimizu Y., Ito T., Nishimura Y., Otsuki T.;
RT   "Enhanced expression of nicotinamide nucleotide transhydrogenase (NNT)
RT   and its role in a human T cell line continuously exposed to
RT   asbestos.";
RL   Environ. Int. 138:105654.1-105654.13(2020).
//